SOX2 and neoplasm: A recent systematic review and meta-analysis assessed the EarlyCDT®-Lung Test, the most-studied panel targeting seven tumor-associated autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE-A4, and SOX2.